Monoclonal Antibody (mAb) Licensing Deal Benchmarks

Median Upfront

$476M

Range: $251M - $691M

Total Deal Value

$2.5B

Range: $1.6B - $3.5B

Royalty Rate

13.2% - 22.1%

Tiered up to 26.1%

Dev Milestones

$406M

Range: $260M - $553M

Model Your Deal

Market Analysis

Monoclonal antibodies remain the backbone of biologic drug development, representing the largest share of biopharma licensing activity by deal count. Phase 2 mAb deals in immunology achieve a median total deal value of $2.5B, with upfront payments from $251M to $691M. The well-characterized development pathway and commercial predictability of mAbs provide deal certainty that newer modalities cannot yet match.

Milestone structures for mAb deals allocate $406M to development, $710M to regulatory, and $913M to commercial milestones. The overall 19/81 upfront/milestone split reflects the de-risked clinical pathway at Phase 2.

Royalty rates for mAb licensing range from 13.2% to 22.1% at the base tier, escalating to 26.1% on peak sales. Differentiated targets, best-in-class efficacy profiles, and subcutaneous formulations command premium royalty rates. Biosimilar exposure risk increasingly influences royalty term negotiations.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average total deal value for a monoclonal antibody licensing deal?

Phase 2 mAb deals in immunology have a median total deal value of $2.5B, with upfronts averaging $476M. Oncology mAbs tend to command higher valuations due to premium pricing and less biosimilar pressure.

How do mAb deal terms differ by therapeutic area?

Immunology mAb deals tend to have larger commercial milestones due to broader patient populations, while oncology mAbs command higher upfronts and royalty rates driven by premium pricing. The modality's established development pathway means deal terms are more predictable than for novel modalities like ADCs or bispecifics.

What royalty rates are standard for mAb licensing deals?

Base royalty rates for mAb deals range from 13.2% to 22.1%, with escalation tiers reaching 26.1%. Rates depend on target novelty, competitive landscape, biosimilar exposure, and whether the antibody has a differentiated mechanism versus existing therapies.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Monoclonal Antibody (mAb) Licensing Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

ADC Deal Benchmarks

Bispecific Antibody Deals

Autoimmune Biologics Deals

Immunology Deal Overview

Ready to Calculate Your Deal Terms?